About EpigenTek
Founded in 2004, EpigenTek specialises in epigenetics research technologies, developing tools that enable researchers to investigate the molecular mechanisms regulating gene expression and genome function. The company focuses on DNA methylation, histone modification, chromatin regulation, RNA methylation and non-coding RNA biology, providing solutions that support both basic and translational research. Its expertise spans epigenomic analysis, biomarker discovery and assay development, helping scientists study disease-associated epigenetic changes in areas including cancer, neuroscience, immunology, ageing and stem cell biology.
EpigenTek’s portfolio includes assay kits, antibodies, enzymes, proteins and reagents for DNA methylation analysis, chromatin immunoprecipitation (ChIP), histone modification studies, RNA epigenetics and epigenome-wide profiling. The company is particularly recognised for its EpiQuik® product range, which supports quantitative analysis of epigenetic biomarkers through user-friendly assay workflows. In addition, EpigenTek provides tools for next-generation sequencing sample preparation, methylation analysis and epigenetic drug discovery research. These products support workflows ranging from biomarker identification and validation to mechanistic studies of gene regulation and disease progression.
Europa Biosite’s subsidiaries distribute for EpigenTek in Belgium, Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Luxembourg, Netherlands, Norway and Sweden.